EUCTR2008-004760-39-FR进行中（未招募）1 期
A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterferon/ribavirin
Schering Plough Research Institute, A Division of Schering Corporation0 个研究点目标入组 198 人开始时间: 2009年3月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. For inclusion in the study, subjects must have a qualifying regimen defined as PEG2a/ribavirin or peginterferon alfa-2b (PEG2b)/ribavirin for a minimum of 12 weeks. If a subject has received more than one such regimen, the most recent regimen is considered the qualifying regimen
- •Note: Maintenance therapy, following failure of qualifying therapy, with any interferon alfa is acceptable; however, the subject must have discontinued the maintenance therapy at least 1 month prior to the Screening Visit
- •2. During the qualifying regimen, subjects must have either:
- •a. A documented undetectable HCV-RNA within 30 days of EOT and a subsequent detectable HCV-RNA during follow-up OR
- •b. A documented decline in HCV-RNA by >/= 2 log10 by TW 12.
- •Note: For subjects who did not participate in Schering-Plough Research Institute (SPRI) protocols, qualifying virology reports and documentation of qualifying previous treatment regimen must be completely de-identified and faxed to the sponsor's project physician for confirmation that the subject qualifies for this study
- •3. Subject must have previously documented CHC genotype 1 infection. Subjects with other or mixed genotypes are not eligible. The HCV-RNA result obtained from the central laboratory at the Screening Visit must confirm genotype 1 infection and be equal or greater than 10,000 IU/mL
- •4. Subject must have a liver biopsy with histology consistent with CHC and no other etiology. Copies of the pathology report and slides are required for the subject to be included in the study. The study site must be able to access the pathology report and histology slides prior to subject randomization. Two unstained slides are preferred; however, one slide stained with hematoxylin plus eosin (H & E) plus one slide stained with Masson’s trichrome will be accepted (slides should be reviewed by the investigator to confirm adequacy). The central pathologist’s reading will be used for analysis purposes
- •a. No cirrhosis: Biopsy must be within 3 years of the Screening Visit
- •b. Cirrhosis: Any historic liver biopsy demonstrating cirrhosis will be accepted regardless of length of time since biopsy
- •c. Subjects whose timing of liver biopsy does not meet this criterion for subject eligibility may have a liver biopsy performed between Screening and Day 1, if their Screening Visit confirms that the subject meets the other study inclusion criteria
- •5. Subjects with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the Screening Visit (or between Screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC)
- •6. Subjects participating in SPRI maintenance protocols P02570 or P02569 must have completed the study (ie, finished last contact) to be eligible for this protocol
- •7. Subject must be 18 years of age
- •8. Subject must weigh between 40 kg and 125 kg
- •9. Subject and subject’s partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations
- •10. Subjects must be willing to give written informed consent
- •Are the trial subjects under 18? no
排除标准
- •1. Subjects known to be coinfected w/HIV or HBV
- •2. Subjects requiring discontinuation of previous interferon or ribavirin regimen for an AE considered to be possibly/probably related to ribavirin &/or interferon
- •3. Treatment w/ribavirin w/in 90 days & any interferon alfa w/in 1 month of Screening
- •4. Treatment for hepatitis C w/any investigational drug. Prior treatment with herbal remedies w/known hepatotoxicity
- •5. Treatment w/any investigational drug w/in 30 days of the randomization
- •6. Participation in any other clinical trial w/in 30 days of randomization
- •7. Evidence of decompensated liver disease including history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy
- •8. Diabetic &/or hypertensive subjects w/clinically significant ocular findings
- •9. Pre-existing psychiatric condition(s), including but not limited to:
- •a. Current moderate or severe depression (mild depression may be enrolled)
- •b. History of depression associated with: Hospitalization; Electroconvulsive therapy; prolonged absence from work &/or significant disruption of daily functions
- •c. Suicidal or homicidal ideation &/or attempt
- •d. History of severe psychiatric disorders
- •e. Past/current use of lithium
- •f. Past/current use of antipsychotic drugs
- •10. Clinical diagnosis of substance abuse of the following drugs w/in the following timeframes:
- •a. Alcohol, intravenous drugs, inhalational (not including marijuana), psychotropics, narcotics, cocain, prescription or over-the-counter drugs: w/in 1 year of the Screening Visit, OR
- •b. Multi-drug abuse w/in 3 years of Screening Visit OR
- •c. Subjects receiving opiate agonist substitution therapy w/in 1 year of Screening (except for subjects monitored in an opioid substitution maintenance program) OR
- •d. Historic marijuana use is deemed excessive by a physician, or is interfering with the subject's life
- •11. Any known pre-existing medical condition that could interfere w/the participation in & completion of study, including but not limited to:
- •a. Central nervous system trauma
- •b. Current or history of seizure disorder unless >10 years ago, a single isolated event, no anti-seizure medications prescribed, & a normal neurological examination documented in study files w/in 6 months of Day 1
- •c. History of stroke/transient ischemic attack
- •d. Immunologically mediated disease
- •e. Chronic pulmonary disease
- •f. Current or history of any clinically significant cardiac abnormalities/dysfunction including current uncontrolled hypertension or history of antianginal agents for cardiac conditions
- •g. Any medical condition requiring chronic systemic administration of corticosteroids during study
- •h. Active clinical gout w/in 1 year
- •i. Hemoglobinopathy
- •j. Myelodysplastic syndromes
- •k. Coagulopathy
- •l. Organ transplants other than corneal & hair
- •m. Poor venous access precluding routine peripheral blood sampling
- •n. Subjects w/indwelling venous catheters
- •o. Subjects w/a history
研究者
相似试验
进行中（未招募）
不适用
A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterferon/ribaviriEUCTR2008-004760-39-BESchering Plough Research Institute, a Division of Schering Corporation198
进行中（未招募）
不适用
A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterferon/ribaviriChronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CMedDRA version: 9.1Level: PTClassification code 10019744Term: Hepatitis CMedDRA version: 9.1Level: SOCClassification code 10021881Term: Infections and infestationsMedDRA version: 9.1Level: SOCClassification code 10019805Term: Hepatobiliary disordersEUCTR2008-004760-39-DESchering Plough Research Institute, A Division of Schering Corporation198
进行中（未招募）
1 期
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriChronic Hepatitis CMedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis CMedDRA version: 9.1 Level: PT Classification code 10019744 Term: Hepatitis CMedDRA version: 9.1 Level: SOC Classification code 10021881 Term: Infections and infestationsMedDRA version: 9.1 Level: SOC Classification code 10019805 Term: Hepatobiliary disordersEUCTR2007-005151-42-FRSchering Plough Research Institute, A Division of Schering Corporation375
进行中（未招募）
1 期
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriChronic Hepatitis CMedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis CMedDRA version: 9.1 Level: PT Classification code 10019744 Term: Hepatitis CMedDRA version: 9.1 Level: SOC Classification code 10021881 Term: Infections and infestationsMedDRA version: 9.1 Level: SOC Classification code 10019805 Term: Hepatobiliary disordersEUCTR2007-005151-42-GBSchering Plough Research Institute, A Division of Schering Corporation375
进行中（未招募）
不适用
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriEUCTR2007-005151-42-PTSchering Plough Research Institute, A Division of Schering Corporation375